FDAnews
www.fdanews.com/articles/129677-celegne-rsquo-s-revlimid-granted-marketing-authorization-in-japan

Celegne’s Revlimid Granted Marketing Authorization in Japan

August 20, 2010
Pharmaceutical company Celgene International said that Revlimid (lenalidomide) has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare for the treatment of patients with myelodysplastic syndromes associated with a deletion 5q cytogenic abnormality.
TradingMarkets